Skip to main content
Clinical Trials/NCT04188288
NCT04188288
Terminated
Not Applicable

Neurofeedback in Individuals With Substance Use Disorders

Yale University1 site in 1 country12 target enrollmentJuly 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Opioid-Related Disorders
Sponsor
Yale University
Enrollment
12
Locations
1
Primary Endpoint
Opioid Use: Urine Tests
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to train individuals with opioid use disorder to control their brain activity in a way that has been associated with their symptoms. Participants in the experimental group will be given direct feedback regarding their brain activity while they are undergoing functional magnetic resonance imaging (fMRI) scanning, and will try to learn to control their brain activity during these feedback sessions. A separate group of participants will be given a control form of feedback that we do not believe can have clinical benefits. Our primary hypothesis is that the neurofeedback training will reduce opioid use and clinical features of opioid use disorder more than the control feedback.

Registry
clinicaltrials.gov
Start Date
July 1, 2021
End Date
March 15, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • non-methadone opioid positive urine screen (as assessed during standard treatment) or indicated via Utox or self-reported past-month opioid use at screening
  • Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for opioid use disorder, as assessed via structured clinical interview (SCID)
  • ≥3 months of methadone treatment

Exclusion Criteria

  • Having any current neurologic or psychiatric disorders including current moderate to severe other DSM-5 substance use disorders with the exceptions of opioids, cocaine, tobacco and cannabis, as assessed using the SCID.
  • Failure to pass a magnetic resonance imaging (MRI) screening
  • Having significant underlying medical conditions requiring medications.
  • Women who are pregnant or nursing
  • Baseline scanning with excessive motion based on frame to frame displacement

Outcomes

Primary Outcomes

Opioid Use: Urine Tests

Time Frame: Baseline (week 1) to one month post follow-up (week 9)

Opioid use will be monitored by weekly urine test. This will be assessed as the percentage of negative tests.

Opioid Use: Timeline Followback Method (TLFB)

Time Frame: Baseline (week 1) to one month post follow-up (week 9)

Opioid use assessed using the timeline followback method (TLFB). TLFB asks subjects to estimate drug use during a specific time period in the past. Number of participants positive or negative for drug use.

Secondary Outcomes

  • Mean Change in Functional Connectivity Patterns in the Brain(Baseline (week 1) through follow up (week 5))
  • Mean Opioid Craving Score(Baseline (week 1) to one month post follow-up (*week 9*))
  • Negative Affect Mean Score(Baseline (week 1) to one month post follow-up (week 9))

Study Sites (1)

Loading locations...

Similar Trials